



Latde Diagnostics.

Guiding antibiotic treatment for all

Emily Melzer, Ph.D.
CEO & Co-founder



www.latde-dx.com

emily@latdedx.com

How do physicians decide which antibiotic to prescribe?



Results to guide treatment for **urinary tract infections** take **up to 3 days**



Latde is developing the **first instrument-free rapid test** to guide **antibiotic prescription within the same day**



10M outpatient visits



Providers: Streamlined clinical workflow


Clinics: New revenue stream

Patients: Effective, safe treatment immediately

Payors: save >\$1B each year

Protect antibiotics for **future generations**

Latde is pairing **Nobel prize winning** chemical tools with **simple, affordable output** lateral flow assay (LFA)



Latde is addressing an unmet need for **rapid, low-cost, instrument-free** antibiotic susceptibility testing

affordable



- Primary care (3M cases)
- Urgent care (4M cases)
- Retail clinics
- University health centers
- Nursing homes
- Military bases

rapid



Market potential for first product

U.S. sales via GPOs

\$50 target price

Global antibiotic susceptibility testing

Latde UTI global

Latde UTI U.S.

\$3B

\$600M

\$65M

Future market opportunities for Latde's platform technology

Infectious
disease
diagnostics

\$20B

Sepsis testing: \$770M
Mastitis
Tuberculosis \$1.7B
fungal \$18M

Food safety

\$20B

Biomedical
manufacturing

\$500M

Veterinary
diagnostics

\$9B

Latde's leadership team brings **clinical and scientific expertise, diagnostics development know-how and entrepreneurial experience**

Founders



Emily Melzer, Ph.D.
CEO, Co-founder




Sloan Siegrist, Ph.D.
CSO, Co-founder

Board of Directors

Maroon Venture
Partners Fund

ALD nanosolutions



Mike Masterson
Board Member,
serial entrepreneur




TruCode Gene
Repair



Mark Fiandaca
in vitro diagnostics
executive

Advisors



**Howard
Smithline, MD**
Emergency
medicine




**James
Keegan, MD**
Infectious Disease
And AMR



**Marcos
Pires, Ph.D.**
Synthetic Chemistry

Latde's past, present and future

Pre-clinical



Patent portfolio

Market validation (users, industry, policymakers)

KOL network


Test validated on clinical UTI isolates from CDC



2021-2024

2025

Latde's past, present and future



Join us to be a part of Latde's impact

Raising \$2M seed to support pre-clinical phase deliverables

Technical

Patient sample
validation

Kit prototype
& workflow

Finalize
commercial
design

Commercialization

IP filings
FTO

FDA pre-
submission

Reimbursement &
market access
strategy

18 months



**Improve clinical
outcomes**



**Antimicrobial stewardship
to protect antibiotics**



**Combat
health inequity**



Thanks for
listening!

Emily Melzer, Ph.D.
emily@latdedx.com
www.latde-dx.com